Effect of Omega-3 And SCFA in Human Hypertension and Cardiovascular Health
DOI:
https://doi.org/10.54097/qq104074Keywords:
Hypertension, omega-3 fatty acids, SCFAs.Abstract
Hypertension is an urgent and increasingly prevalent issue in global public health. Its regulation through diet has become a crucial focus. Dietary Omega-3 and SCFA have demonstrated multiple health benefits, including the blood pressure management. This article delves into their effects and mechanism on hypertension in humans. Epidemiological and clinical studies provide empirical support for the assertion that the intake of PUFA is correlated with reduced cardiovascular mortality. This reduction is achieved through various mechanisms, such as control of cellular metabolic pathways, alteration of gene transcription patterns, and favorable effects on control of blood pressure and lipid. Furthermore, this article also analyzed the effects of SCFA on hypertension. The utilization of dietary fiber by intestinal flora resulting in the synthesis of several SCFAs which subsequently influence hypertension. Additionally, a correlation exists between hypertension and gut microbiota composition, with significant variations observed in the gut microbiota composition among spontaneously hypertensive groups.
Downloads
References
Wu Y, Xu H, Tu X, et al. The role of short-chain fatty acids of gut microbiota origin in hypertension. Front Microbiol, 2021, 12: 730809.
Wang H, Li Q, Zhu Y, et al. Omega-3 polyunsaturated fatty acids: versatile roles in blood pressure regulation. Antioxid Redox Sign, 2021, 34 (10): 800 - 810.
Valensi P. Hypertension, single sugars and fatty acids. J Hum Hypertens, 2005, 19 (3): S5 - S9.
Coletta J M, Bell S J, Roman A S. Omega-3 fatty acids and pregnancy. Rev Obstetr Gyneco, 2010, 3 (4): 163.
Director W C. What can we expect from omega-3 fatty acids? Clev Clin J Med, 2009, 76 (4): 245.
May K S, den Hartigh L J. Modulation of adipocyte metabolism by microbial short-chain fatty acids. Nutrients, 2021, 13 (10): 3666.
van der Hee B, Wells J M. Microbial regulation of host physiology by short-chain fatty acids. Trends Microbiol, 2021, 29 (8): 700 - 712.
Engler M M. Role of dietary omega-3 fatty acids in hypertension. Ann Nurs Pract, 2017, 4 (1): 1077.
Yang F, Chen H, Gao Y, et al. Gut microbiota-derived short-chain fatty acids and hypertension: Mechanism and treatment. Biomed Pharmacother, 2020, 130: 110503.
Kim S, Goel R, Kumar A, et al. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clin Sci, 2018, 132 (6): 701 - 718.
Yang T, Magee K, Malphurs W, et al. Microbial metabolite, butyrate, increases blood pressure in rodent models of hypertension. The FASEB Journal, 2017, 31: 1011.22 - 1011.22.
Mell B, Jala V R, Mathew A V, et al. Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol Genomics, 2015, 47 (6): 187 - 197.
Onyszkiewicz M, Gawrys-Kopczynska M, Sałagaj M, et al. Valeric acid lowers arterial blood pressure in rats. Eur J Pharmacol, 2020, 877: 173086.
Marques F Z, Nelson E, Chu P Y, et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation, 2017, 135 (10): 964 - 977.
Yang T, Santisteban M M, Rodriguez V, et al. Gut dysbiosis is linked to hypertension. hypertension, 2015, 65 (6): 1331 - 1340.
Li J, Zhao F, Wang Y, et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome, 2017, 5: 1 - 19.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
